JPWO2016133069A1 - 心不全の予防又は治療のための医薬 - Google Patents
心不全の予防又は治療のための医薬 Download PDFInfo
- Publication number
- JPWO2016133069A1 JPWO2016133069A1 JP2017500675A JP2017500675A JPWO2016133069A1 JP WO2016133069 A1 JPWO2016133069 A1 JP WO2016133069A1 JP 2017500675 A JP2017500675 A JP 2017500675A JP 2017500675 A JP2017500675 A JP 2017500675A JP WO2016133069 A1 JPWO2016133069 A1 JP WO2016133069A1
- Authority
- JP
- Japan
- Prior art keywords
- heart failure
- administration
- treatment
- patients
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 230000002265 prevention Effects 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title description 12
- UBVZQGOVTLIHLH-UHFFFAOYSA-N 4-[5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl]-pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC(C=2N=C(NN=2)C=2C=CN=CC=2)=C1 UBVZQGOVTLIHLH-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 11
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 5
- 230000009798 acute exacerbation Effects 0.000 claims description 2
- 229950004176 topiroxostat Drugs 0.000 abstract description 12
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 27
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 27
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 27
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 27
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 10
- 229960003459 allopurinol Drugs 0.000 description 9
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 5
- 229960005101 febuxostat Drugs 0.000 description 5
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 2
- -1 calcium antagonists Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007560 Cardiac failure high output Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 206010059284 Epidermal necrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019271 high output heart failure Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)4−[5−(ピリジン−4−イル)−1H−1,2,4−トリアゾール−3−イル]ピリジン−2−カルボニトリル(一般名:トピロキソスタット)を有効成分とする、心不全の予防又は治療のための医薬。
(2)前記心不全が、慢性心不全、慢性心不全の急性増悪、及び急性心不全からなる群から選択される(1)に記載の医薬。
[研究方法]
種々の基礎心疾患により、心不全重症度分類NYHAII〜IVに相当する患者で、かつキサンチンオキシダーゼ阻害薬(XO阻害剤)の類薬であるアロプリノール又はフェブキソスタット投与中の患者を対象に、それまでの心不全治療を継続した上で、アロプリノール又はフェブキソスタットからトピロキソスタット投与に切り替えることによって、心機能マーカーである血中BNP値に対する影響を評価した。また、類薬非投与の患者についても、同様に、トピロキソスタット投与による血中BNP値低下の影響を6か月間に亘り評価した。尚、トピロキソスタット投与中は、特に血中BNP値に影響するとされる利尿剤等の新たな追加や用法・用量の変更などは行わなかった。尚、対象とした患者は15例で男性13例、女性2例であり、年齢は67-94歳であった。そのうち、トピロキソスタット投与前の類薬別症例13例の内訳は、アロプリノール2例、フェブキソスタット11例であった。類薬非投与患者は2例であった。また、トピロキソスタット投与前のアロプリノール又はフェブキソスタット投与期間中(3か月間)の血中BNP値は有意な変動を示さなかった。
対象とした15例全例のトピロキソスタット投与による血中BNP値の推移は、投与前469±278pg/ml(平均±SD)、投与3か月後には296±232pg/mlへと著明に低下し、投与6か月後(最終評価時)には254±129pg/mlとさらに低下した。15例の最終評価時における投与開始前からの血中BNP値の変化量の平均値とその95%信頼区間は、-215±238pg/ml(-347pg/ml, -83pg/ml)と有意に低下した(t検定、P=0.0036)。
同様に、類薬であるアロプリノール又はフェブキソスタット投与中の心不全患者13例を対象にトピロキソスタットに切り替えた場合の血中BNP値の推移は、投与前431±272pg/ml(平均±SD)から、投与3か月後には293±243pg/mlへと著明に低下し、投与6か月後(最終評価時)には248±136pg/mlとさらに低下した。
また、類薬非投与の患者2例の投与前から投与6か月後(最終評価時)の血中BNP値の変化量は、各々-184pg/ml及び-660pg/mlと顕著な低下を示した。
対象とした15例の血中BNP値のトピロキソスタット投与後の推移を図1に示した。心機能マーカーである血中BNP値の変化量は、投与3か月という早期に平均で-173pg/mlと45%も低下させた。中等度以上の心不全ではBNP 10pg/mlの上昇で心血管死亡率が6年あたり3%ずつ上昇するとの報告(非特許文献2)からすると、トピロキソスタット投与による血中BNP値低下量は驚くべきことである。また、投与前値の平均値469pg/mlはNYHA分類ではおよそIII度に相当する心不全重症度であり、3、6か月後の血中BNP値の各々の平均値296pg/ml、254pg/mlはおよそII度に相当する。この血中BNP値の低下量(平均-215pg/ml)は心不全重症度(NYHA重症度)を1度相当改善したという点で、特に心血管死亡率の低下の可能性など医療上のメリットのみならず、再入院率の低下の可能性等、医療経済的なメリットも大きいことが示唆された。
従来治療での血中BNP値低下が不十分な患者に対しても、トピロキソスタットの併用、あるいは類薬からの切替により、優れた血中BNP値低下、即ち、心不全に対する予防及び治療効果が得られた。これらの効果は、当業者の予測を遙かに超えたものである。
Claims (2)
- 4−[5−(ピリジン−4−イル)−1H−1,2,4−トリアゾール−3−イル]ピリジン−2−カルボニトリル(一般名:トピロキソスタット)を有効成分とする、心不全の予防又は治療のための医薬。
- 前記心不全が、慢性心不全、慢性心不全の急性増悪、及び急性心不全からなる群から選択される請求項1記載の医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015028707 | 2015-02-17 | ||
JP2015028707 | 2015-02-17 | ||
PCT/JP2016/054392 WO2016133069A1 (ja) | 2015-02-17 | 2016-02-16 | 心不全の予防又は治療のための医薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016133069A1 true JPWO2016133069A1 (ja) | 2018-01-25 |
JP6684264B2 JP6684264B2 (ja) | 2020-04-22 |
Family
ID=56689011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017500675A Expired - Fee Related JP6684264B2 (ja) | 2015-02-17 | 2016-02-16 | 心不全の予防又は治療のための医薬 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6684264B2 (ja) |
WO (1) | WO2016133069A1 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04004037A (es) * | 2002-01-28 | 2004-07-23 | Fuji Yakuhin Co Ltd | Compuestos novedosos de 1, 2, 4-de triazol. |
US20040122067A1 (en) * | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
JP2008088107A (ja) * | 2006-10-02 | 2008-04-17 | Fujiyakuhin Co Ltd | 新規ピリダジン誘導体 |
-
2016
- 2016-02-16 WO PCT/JP2016/054392 patent/WO2016133069A1/ja active Application Filing
- 2016-02-16 JP JP2017500675A patent/JP6684264B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP6684264B2 (ja) | 2020-04-22 |
WO2016133069A1 (ja) | 2016-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mullens et al. | The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology | |
Feldheiser et al. | Enhanced Recovery After Surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice | |
Aronow | Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure | |
Kumthekar et al. | Metformin associated B12 deficiency | |
EP2808018A1 (en) | Therapeutic agent for diabetes | |
JP6509729B2 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
Faro et al. | Left ventricular hypertrophy in children, adolescents and young adults with sickle cell anemia | |
Ward et al. | First clinical experience with ONO-4232: a randomized, double-blind, placebo-controlled healthy volunteer study of a novel lusitropic agent for acutely decompensated heart failure | |
WO2021105164A1 (en) | Pharmaceutical composition for the treatment of pulmonary vascular disease and/or cardiac dysfunction in fontan-palliated patients | |
WO2016133069A1 (ja) | 心不全の予防又は治療のための医薬 | |
KR102512518B1 (ko) | 페마피브레이트를 함유하는 의약 | |
KR20220004643A (ko) | 신규 의약 조성물 | |
US20040176387A1 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
Meyer et al. | Sex differences in early dyspnea relief between men and women hospitalized for | |
TWI674094B (zh) | 治療或緩解慢性骨髓性白血病用之醫藥組合物 | |
Safdar et al. | Longitudinal Use of Midodrine to Optimize Pulmonary Hypertension Therapies | |
AU2022320922A1 (en) | Dose regimen for long-acting glp1/glucagon receptor agonists | |
Laurent et al. | [PP. 13.13] ONE MONTH BLOOD PRESSURE LOWERING EFFICACY RESULTS OF A NOVEL FIRST-LINE TREATMENT IN HYPERTENSION | |
Mirakbarovna et al. | Study of the clinical efficacy of a combination of beta-blockers and calcium antagonists in older patients with coronary heart disease in combination with hypertension | |
JP6414727B2 (ja) | 関節疾患の治療予防剤 | |
JP2007008845A (ja) | 慢性心不全治療および/または予防薬 | |
Paterno et al. | [PP. 13.11] BENEFIT IN CENTRAL HAEMODYNAMIC PARAMETERS BY ASSOCIATION ANGIOTENSIN II RECEPTOR BLOCKERS AND CANRENONE THERAPY IN HYPERTENSIVE PATIENTS WITH NORMAL KIDNEY FUNCTION | |
Park et al. | Application of torsemide to two dogs with congestive heart failure | |
CN106540257A (zh) | 一种老年高血压的诊断与治疗的方法 | |
Norcross et al. | I. Overview. Heart failure (HF) affects 4.8 million persons in the United States. HF is the only cardiovascular disorder whose incidence and prevalence are increasing, especially in the elderly and in women. This diagnosis accounts for 11 million out-patient visits and 3 million hospitalizations annually, with costs exceeding $20 bil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170523 |
|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20171107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171117 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200317 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200327 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6684264 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |